Cargando…

Population pharmacokinetic‐pharmacodynamic modelling of platelet time‐courses following administration of abrocitinib

AIMS: Abrocitinib is a selective Janus kinase 1 inhibitor for the treatment of moderate‐to‐severe atopic dermatitis. Herein we describe the time‐course of drug‐induced platelet reduction following abrocitinib administration, identify covariates affecting platelet counts, and determine the probabilit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wojciechowski, Jessica, Malhotra, Bimal K., Wang, Xiaoxing, Fostvedt, Luke, Valdez, Hernan, Nicholas, Timothy
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9544602/ https://www.ncbi.nlm.nih.gov/pubmed/35342978 http://dx.doi.org/10.1111/bcp.15334

Ejemplares similares

Population Pharmacokinetics of Abrocitinib in Healthy Individuals and Patients with Psoriasis or Atopic Dermatitis
por: Wojciechowski, Jessica, et al.
Publicado: (2022)

Correction to: Population Pharmacokinetics of Abrocitinib in Healthy Individuals and Patients with Psoriasis or Atopic Dermatitis
por: Wojciechowski, Jessica, et al.
Publicado: (2022)

Population Pharmacokinetic/Pharmacodynamic Modeling of the Effect of Abrocitinib on QT Intervals in Healthy Volunteers
por: Wang, Xiaoxing, et al.
Publicado: (2022)

Effects of Hepatic Impairment on the Pharmacokinetics of Abrocitinib and Its Metabolites
por: Wang, Ellen Q., et al.
Publicado: (2021)

Effects of Renal Impairment on the Pharmacokinetics of Abrocitinib and Its Metabolites
por: Wang, Ellen Q., et al.
Publicado: (2022)

Assessment of the Effects of Inhibition or Induction of CYP2C19 and CYP2C9 Enzymes, or Inhibition of OAT3, on the Pharmacokinetics of Abrocitinib and Its Metabolites in Healthy Individuals
por: Wang, Xiaoxing, et al.
Publicado: (2022)

Kinetic‐Pharmacodynamic Model of Platelet Time Course in Patients With Moderate‐to‐Severe Atopic Dermatitis Treated With Oral Janus Kinase 1 Inhibitor Abrocitinib
por: Soto, Elena, et al.
Publicado: (2020)

Pharmacokinetic/Pharmacodynamic Modeling to Support the Re‐approval of Gemtuzumab Ozogamicin
por: Fostvedt, Luke K., et al.
Publicado: (2019)

Abrocitinib: First Approval
por: Deeks, Emma D., et al.
Publicado: (2021)

Evaluation of the Effect of Abrocitinib on Drug Transporters by Integrated Use of Probe Drugs and Endogenous Biomarkers
por: Vourvahis, Manoli, et al.
Publicado: (2022)

Correction to: Abrocitinib: First Approval
por: Deeks, Emma D., et al.
Publicado: (2022)

Population Pharmacokinetic and Pharmacodynamic Modeling of Fesoterodine in Pediatric Patients with Neurogenic Detrusor Overactivity
por: Sano, Yamato, et al.
Publicado: (2023)

Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial
por: Silverberg, Jonathan I., et al.
Publicado: (2020)

Pharmacokinetics and pharmacodynamics of intra-articular isoflupredone following administration to horses with lipopolysaccharide-induced synovitis
por: Knych, Heather K., et al.
Publicado: (2022)

Rapidity of Improvement in Signs/Symptoms of Moderate-to-Severe Atopic Dermatitis by Body Region with Abrocitinib in the Phase 3 JADE COMPARE Study
por: Alexis, Andrew, et al.
Publicado: (2022)

A Case of Perioral Dermatitis Successfully Treated with Abrocitinib
por: Teng, Yan, et al.
Publicado: (2023)

Durability of Response to Abrocitinib in Patients with Moderate-to-Severe Atopic Dermatitis After Treatment Discontinuation in a Phase 2b Trial
por: Gooderham, Melinda J., et al.
Publicado: (2022)

Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Integration of Enrofloxacin Following Single Oral Administration of Different Doses in Brown Trout (Salmo trutta)
por: Uney, Kamil, et al.
Publicado: (2021)

Pharmacokinetic and Pharmacodynamic Target Attainment in Adult and Pediatric Patients Following Administration of Ceftaroline Fosamil as a 5‐Minute Infusion
por: Riccobene, Todd A., et al.
Publicado: (2021)

Pharmacokinetic Behavior and Pharmacokinetic/Pharmacodynamic Integration of Danofloxacin Following Single or Co-Administration with Meloxicam in Healthy Lambs and Lambs with Respiratory Infections
por: Ural, Mehmet Nihat, et al.
Publicado: (2021)

Efficacy and Safety of JAK1 Inhibitor Abrocitinib in Atopic Dermatitis
por: Iznardo, Helena, et al.
Publicado: (2023)

A Report of Eruptive Pruritic Papular Porokeratosis Treated with Abrocitinib
por: Xia, Jiali, et al.
Publicado: (2023)

Efficacy and Safety of Abrocitinib in Combination With Topical Therapy in Adolescents With Moderate-to-Severe Atopic Dermatitis: The JADE TEEN Randomized Clinical Trial
por: Eichenfield, Lawrence F., et al.
Publicado: (2021)

Pharmacokinetics and Pharmacodynamics of Posaconazole
por: Chen, Lu, et al.
Publicado: (2020)

Pharmacokinetics and Pharmacodynamics of Ibrexafungerp
por: McCarthy, Matthew William
Publicado: (2021)

Pharmacokinetics and Pharmacodynamics of Tedizolid
por: Iqbal, Khalid, et al.
Publicado: (2022)

Population Pharmacokinetic/Pharmacodynamic Analysis of Nociceptive Pain Models Following an Oral Pregabalin Dose Administration to Healthy Subjects
por: van Esdonk, Michiel J., et al.
Publicado: (2018)

Utility of systemic voriconazole in equine keratomycosis based on pharmacokinetic‐pharmacodynamic analysis of tear fluid following oral administration
por: Tamura, Norihisa, et al.
Publicado: (2020)

Pharmacokinetics and pharmacodynamics of acetylsalicylic acid after intravenous and oral administration to healthy volunteers
por: Nagelschmitz, J, et al.
Publicado: (2014)

Pharmacokinetics and Pharmacodynamics of an Oral Formulation of Apixaban in Horses After Oral and Intravenous Administration
por: Serpa, Priscila B. S., et al.
Publicado: (2018)

Pharmacokinetics, Pharmacodynamics, and Tolerability of Concomitant Administration of Verinurad and Febuxostat in Healthy Male Volunteers
por: Hall, Jesse, et al.
Publicado: (2018)

Pharmacokinetic–pharmacodynamic modelling of the hypoglycaemic effect of pulsatile administration of human insulin in rats
por: Miyazaki, Makoto, et al.
Publicado: (2020)

Pharmacokinetics and pharmacodynamics of intranasal and intramuscular administration of naloxone in working dogs administered fentanyl
por: Barr, Ciara A., et al.
Publicado: (2023)

Pharmacokinetic and Pharmacodynamic Considerations in Antimalarial Dose Optimization
por: White, Nicholas J.
Publicado: (2013)

Effects of renal function on pharmacokinetics and pharmacodynamics of lesinurad in adult volunteers
por: Gillen, Michael, et al.
Publicado: (2016)

Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program
por: Simpson, Eric L., et al.
Publicado: (2021)

Economic impact of abrocitinib monotherapy and combination therapy in patients with moderate-to-severe atopic dermatitis: Results from JADE MONO-2 and JADE COMPARE
por: Gooderham, Melinda J., et al.
Publicado: (2021)

The Pharmacokinetics and Pharmacodynamics of Iron Preparations
por: Geisser, Peter, et al.
Publicado: (2011)

Clinical Pharmacokinetics and Pharmacodynamics of Lenalidomide
por: Chen, Nianhang, et al.
Publicado: (2016)

Clinical Pharmacokinetics and Pharmacodynamics of Micafungin
por: Wasmann, Roeland E., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_4cve5rubnbdr7b541o1mpgkrjd